USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/19160
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNiță, Vladislav-
dc.date.accessioned2021-12-06T10:19:00Z-
dc.date.available2021-12-06T10:19:00Z-
dc.date.issued2021-
dc.identifier.citationNIȚĂ, Vladislav. Updates in the diagnostics of insulinoma: [poster]. In: Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021: culegere de postere. 2021, p. 120.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/19160-
dc.descriptionDepartment of Surgery no. 2, scientific research laboratory "Reconstructive surgery of the digestive tract„ SUMPh ”Nicolae Testemițanu” , PMSI CRH ”Timofei Moșneaga”en_US
dc.description.abstractIntroduction: Insulinomas are rare neoplasias with incidence of 1-4 cases per million population annually, but still most common from pancreatic neuroendocrine tumours.Purpose: An analysis of the sensitivity and specificity of insulinoma diagnostic methods. Material and methods: Here are discussed diagnostic data of 15 patients with insulinoma between 1993 and 2021 from clinic no. 1 of the surgery department no. 2. Diagnosis rely on clinical presentation, laboratory findings (glycemic profile, glucose levels during hypoglycemic accesses, convulsive attacks, after 40% glucose solution administration, as well as levels of seric insulin and C-peptide) and imagistic methods as ultrasonography (Figure. 2), CT (Figure.3), MRI (Figure .4). Results: Clinical presentation are dominated by neuropsychic symptoms 13 (86,6%) cases, followed by adrenergic symptoms 10 (66,7%) cases, digestive symptoms 8 (53,3%) cases, and cushingoid manifestations 3 (20%) cases (Figure 1). Glucose levels during hypoglycemic attacks were between 2,0-3,0 mmol/l, after 40% glucose solution infusion - 3,8-5,8 mmol/l. Median level of Cpeptide was 4,6 ng/l , of insulin was 32,45 µmol/l. Imagistic was found tumours between 0,8 and 2,5 cm in size, 10 (66,4%) cases in corporeal site (Figure.2 , Figure.4) and 5 (33,6%) cases in caudal site (Figure.3). Conclusions: The diagnostic of an insulinoma is still a dilemma, relying mostly on clinical manifestations and laboratory findings while there are no unanimously accepted imagistical criteria.en_US
dc.language.isoenen_US
dc.publisherUniversitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" din Republica Moldovaen_US
dc.relation.ispartofConferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021en_US
dc.subjectinsulinomaen_US
dc.subjectpancreatic neuroendocrine tumorsen_US
dc.subjecthyperinsulinemic hypoglycemiaen_US
dc.titleUpdates in the diagnostics of insulinomaen_US
dc.typeOtheren_US
Appears in Collections:Conferinţa ştiinţifică anuală "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță", 20-22 octombrie 2021: Culegere de postere

Files in This Item:
File Description SizeFormat 
Updates_in_the_diagnostics_of_insulinoma.pdf489.08 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback